Skip to main navigation Skip to search Skip to main content

Corrigendum to “ 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling” [Canc. Lett. 471 (2020) 135–146, (S030438351930607X), (10.1016/j.canlet.2019.11.041)]

Research output: Contribution to journalComment/debate

Abstract

The authors regret < In the original version of this article, we found some errors in some figures. The possible reason is that we erroneously mixed the representative pictures of the same or adjacent groups accidently. At present, we have reorganized the data, and made sure that they are correct. Importantly, this error did not change the results and conclusions of this paper. In Figure 3A, BxPC-3 cells were treated with different doses of 2HF (DMSO, 30, 40, 50 μM) for 24 h and flow cytometric analysis detected cell cycle distribution. The representative pictures of 40 μM and 50 μM groups were mixed with 30 μM group. The results still showed that 2HF caused a significant G1/G2 phase arrest in BxPC-3 cells in a dose-dependent manner after a 24 h exposure. In Figure 4B, the representative picture of invasion group was chose wrongly by accident in MIA PaCa-2 cells treated with 2-HF for 20 μM. In Figure 5B, the WB result of STAT3 in MIA PaCa-2 cells was mixed accidently with adjacent group of BxPC-3 cells. >.[Formula presented][Formula presented][Formula presented] I am sorry for the errors. We expect to correct them. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number215913
JournalCancer Letters
Volume549
DOIs
StatePublished - 28 Nov 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Corrigendum to “ 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling” [Canc. Lett. 471 (2020) 135–146, (S030438351930607X), (10.1016/j.canlet.2019.11.041)]'. Together they form a unique fingerprint.

Cite this